Table 1.
Clinical trials testing different CDK1-inhibiting drugs.
| Drug (Targeted CDKs) | Clinical Trial Phase | Disease (Number of Patients) |
Efficacy | Tolerability | Observations | Reference |
|---|---|---|---|---|---|---|
| AZD5438 (1, 2, 9) |
Phase I | Advanced solid tumours (64, 8 pancreatic) | − | − − | [71] | |
| Dinaciclib (1, 2, 5, 9) |
Phase I | Pancreatic cancer (39) | − | + | In combination with MK-2206 (Akt inhibitor) | [68] |
| Advanced malignancies (61, 5 pancreatic) | − + | + | [67] | |||
| Advanced malignancies(48, 4 pancreatic) | − + | − + | [69] | |||
| Phase II | Advanced breast cancer (39) | − + | + | In comparison vs. capecitabine (similar but not superior anticancer activity) | [67] | |
| Refractory multiple myeloma (27) | ++ | + | [66] | |||
| Phase III | Refractory chronic lymphocytic leukemia (42) | + + | + | In comparison vs. ofatumumab (results suggest superior anticancer activity) | [65] | |
| Flavopiridol (1, 2, 4, 6) |
Phase II | Pancreatic cancer (10) | + − | − − | In combination with docetaxel | [70] |
| Milciclib (1, 2, 4, 5) |
Phase I | Refractory solid tumours (16, 13 pancreatic) | + | + + | In combination with gemcitabine | [73] |
| Phase II | Hepatocellular carcinoma (14) | + | + + | [74] | ||
| PHA-848125AC (1, 2, 4, 5, 7) |
Phase I | Advanced solid malignancies (37, 5 pancreatic) | + | − + | [75] | |
| PHA-793887 (1, 2, 4) |
Phase I | Solid tumours (19, 5 pancreatic) | − | − − | [72] |